Recent data from the FELIX trial evaluating obecabtagene autoleucel in patients with relapsed and/or refractory B acute lymphoblastic leukaemia (R/R B-ALL) suggest that this novel intermediate-affinity CD19-directed chimeric antigen receptor (CAR) T cell therapy is associated with a reduced incidence of severe immune-mediated toxicities compared with other commercially available CAR T cell products. The increasing number of therapies available for B-ALL makes treatment selection and sequencing of therapies increasingly challenging.
This is a preview of subscription content, access via your institution
Access options
/* style specs start */ /* style specs end */
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
Purchase on SpringerLink Instant access to full article PDF Buy now
Prices may be subject to local taxes which are calculated during checkout
/* style specs start */ style { display: none !important; } .LiveAreaSection * { align-content: stretch; align-items: stretch; align-self: auto; animation-delay: 0s; animation-direction: normal; animation-duration: 0s; animation-fill-mode: none; animation-iteration-count: 1; animation-name: